Independent Conference Highlights of the 2025 European Lung Cancer Congress *

Review slidesets, a ClinicalThought commentary, and expert analysis of key data from the 2025 ELCC.

Share

Program Content

6 Capsule Summaries

Activities

SAVANNAH
SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 02, 2025

Expires: October 01, 2025

LAURA Updated OS
LAURA: Updated Overall Survival for Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy for Unresectable Stage III EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 09, 2025

Expires: October 08, 2025

SOHO 01
SOHO-01: Phase I/II Study of BAY 2927088 for Previously Treated HER2-Mutant NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 09, 2025

Expires: October 08, 2025

EMPOWER Lung 1
EMPOWER-Lung 1: Cemiplimab Continuation Plus Chemotherapy After Progression on 1L Cemiplimab Monotherapy in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2025

Expires: October 09, 2025

MARIPOSA
MARIPOSA: Final Overall Survival of First-line Amivantamab + Lazertinib vs Osimertinib for Untreated EGFRm Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2025

Expires: October 09, 2025

ORCHARD
ORCHARD: Phase II Study of Osimertinib + Datopotamab Deruxtecan in Advanced EGFRm NSCLC After 1L Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 10, 2025

Expires: October 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.